A phase 2, open-label, dose escalation study to assess the safety and efficacy of ISIS 301012 as add-on therapy in homozygous familial hypercholesterolemia subjects.

Trial Profile

A phase 2, open-label, dose escalation study to assess the safety and efficacy of ISIS 301012 as add-on therapy in homozygous familial hypercholesterolemia subjects.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Aug 2016

At a glance

  • Drugs Mipomersen (Primary)
  • Indications Hyperlipoproteinaemia type II
  • Focus Therapeutic Use
  • Sponsors Genzyme Corporation
  • Most Recent Events

    • 24 Jan 2008 Status changed from in progress to completed (source: ClinicalTrials.gov).
    • 10 Oct 2007 Drug named changed from ISIS 301012 to mipomersen sodium (INN).
    • 16 Feb 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top